People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Immunovant, Inc. | — | Pharmaceuticals | Growth/Late | $450.0M | $5.0B | 2025 |
Christopher Van Tuyl at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Van Tuyl on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Frank Torti | 1 | 3 |
| Douglas Hughes | 1 | 2 |
| Andrew Fromkin | 1 | 2 |
| Atul Pande | 1 | 1 |
| George Migausky | 1 | 1 |
| Eric Venker | 1 | 1 |
| Michael Geffner | 1 | 1 |
| Pete Salzmann | 1 | 1 |
| Jay Stout | 1 | 1 |
| Melanie Gloria | 1 | 1 |
| Eva Renee Barnett | 1 | 1 |
| Bill Macias | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.